The FDA should commit resources and expertise to correct the deeply entrenched public misperceptions regarding the health risks of nicotine, Paige Magness, Altrias senior vice president of regulatory affairs, said in the letter dated February 25
Despite the variety of available treatment modalities, UC remains a poorly disease, although research has shown that its development may be related to genetic, environmental, and immune factors 10
For example, nicotine gum, patches, and inhalators, which have years of data behind them to prove their efficacy and minimise risks. You can also read more on tobacco dependence, and replacement methods from the National Institute of Health and Care Excellence (NICE)
Archived from the original on October 30, 2018